Loading clinical trials...
Loading clinical trials...
Efficacy of Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (HLH) in Children: a Phase 2, Multicentre, Non-comparative Study
Conditions
Interventions
Ruxolitinib
Locations
1
France
Hopital Necker Enfants malades
Paris, Île-de-France Region, France
Start Date
November 10, 2024
Primary Completion Date
May 1, 2027
Completion Date
March 1, 2028
Last Updated
April 23, 2026
NCT05702502
NCT01818492
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions